Efficacy, safety and patient reported outcomes in patients with active relapsing multiple sclerosis treated with ocrelizumab: Final results from the PRO-MSACTIVE study

Eric Manchon,David Laplaud,Sandra Vukusic,Pierre Labauge,Thibault Moreau,Gisela Kobelt,Jean-Marie Grouin,Marie Lotz,David Pau,Lebrun Frenay Christine

Multiple Sclerosis and Related Disorders（2022）

引用 4|浏览1

暂无评分

摘要

•PRO-MSACTIVE evaluated ocrelizumab in patients with active RMS.•This phase IV study tended to mimic current clinical practice.•Disease activity was assessed by clinical and/or imaging features.•Efficacy and safety profile of ocrelizumab is confirmed in a pragmatic setting.•PRO data allowed a better understanding of MS impact on patients’ lives.

查看译文

关键词

Ocrelizumab,Relapsing multiple sclerosis,Phase IV

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要